New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 4, 2013
15:38 EDTMDXGMiMedx disagrees with FDA position, reiterates FY13, FY14 guidance
MiMedx Group confirmed that it is in receipt of an "Untitled Letter" from the Food and Drug Administration. The company further announced that it expressly disagrees with the position in the letter and has been in conversation with the FDA to resolve the matter as quickly as possible. The letter questions the Company's Amnion / Chorion Injectable products' eligibility for marketing solely under Section 361 of the Public Health Service Act. COO Bill Taylor commented, "The Company was surprised by this letter considering the FDA conducted a directed inspection of our facility in July 2012, one of the express purposes of which was to 'determine the status of the [Company's] AmnioFix injectable product.' The inspection report indicated that 'information regarding the [Company's] AmnioFix Injectable product, which was rolled out August 2011, was collected and forwarded to CBER for review. The information collected included advertising, packaging, process procedures and studies conducted related to the product.' Following that inspection, the inspector advised us that CBER had completed its review and had no findings or further questions and, therefore, the inspection was classified as NAI, or No Action Indicated. The formal establishment inspection report confirming the NAI conclusion was issued on December 4, 2012." MiMedx said it proceeded with marketing the injectable product only after receiving advice from outside legal counsel that the product met the criteria for regulation as an HCT/P under Section 361 of the Public Health Service Act. The company said it believes the FDA's conclusion is based on a misunderstanding of the micronization process and is responding to the Untitled Letter and will reiterate its request for a meeting with the FDA. The company reiterated its expected revenue range for 2013 of $54M-$60M and its 2014 goal of $90M-$110M. The revenues from the company's injectable are projected to be approximately 15% of the company's 2014 revenues. CEO Parker "Pete" Petit stated, "Based on other precedents, the Company believes it should be able to continue to sell its injectable products, but even if that not the case, management believes it can refocus its resources to achieve its stated revenue goals."
News For MDXG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
08:06 EDTMDXGMiMedx reports abstracts to be presented at Desert Foot Conference
MiMedx Group announced that fourteen poster abstracts chronicling the company's dehydrated human amnion/chorion membrane allografts to be clinically effective and cost effective in the healing of chronic wounds, difficult lower extremity wounds that have failed prior wound treatment modalities, challenging surgical wounds, chronic neuropathic wounds, wounds threatening the loss of limbs, and other hard-to-heal wounds will be presented at the 11th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona, beginning November 19, and concluding on November 21.
November 17, 2014
16:06 EDTMDXGMiMedx reports results of EpiFix vs. Apligraf comparative study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use